NCT04057924View on ClinicalTrials.gov

Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 23, 2019

Primary Completion Date

September 1, 2029

Study Completion Date

September 1, 2029

Conditions
HPV InfectionCervical Cancer
Interventions
OTHER

abstention from CIN2 treatment and surveillance for at least 2 years

Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years

Trial Locations (1)

Unknown

RECRUITING

CHU Bordeaux, Bordeaux

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER